Full-Time

Vice President

Head of Portfolio, Programs and Alliance Management, Ppam

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Genomics
Public Health
Biology & Biotech
Requirements
  • An advanced degree in life sciences, business or engineering
  • 15+ years of industry leadership experience with 10+ years in program leadership and/or alliance management
  • A minimum of 7 years as a people manager
  • Experience as program leader or in business operations roles
  • Strong understanding of cross-functional drug development from preclinical development through commercialization
  • Demonstrated ability to bridge science and business interests
  • Excellent written and verbal communication skills
  • Being well-versed in program management principles, practices, and tools (including Office Timeline, Think-Cell, and Smartsheet/Microsoft Project)
  • Thriving in a dynamic and rigorous work environment, coaching and mentoring
  • It’s a bonus if you have your Project Management Professional (PMP®) certification or experience in genetic medicines
Responsibilities
  • Establishing the vision and strategy for the PPAM function and being accountable for the overall framework for how programs and alliances are managed and advanced at Tessera
  • Guiding and empowering Program Managers to drive the development and management of integrated program plans (including timelines, assumptions, scenarios, risks, critical path, decision maps, goals, and budget drivers)
  • Establishing and continuously improving PPAM capabilities, tools, and practices
  • Leading management and facilitating governance forums, programs strategy and programs/portfolio prioritization
  • Partnering with Finance and Corporate Development to prepare for Portfolio Reviews
  • Facilitating and contributing to the Programs/Portfolio goal setting & tracking, in line with enterprise goals
  • Systematically monitoring program risks and trends across the portfolio. Ensuring timely escalation of issues and proposed mitigation strategies as appropriate
  • Engaging with functional and enterprise leadership to resolve resource challenges and remove roadblocks
  • Fostering an enriching and positive work environment, maximizing impact
  • Promoting crisp, transparent, and timely communication, clear decision-making in accordance with Tessera’s decision-making model, and high‑performing program/alliance teams
  • Evolving your role over time to meet Tessera’s business needs
  • Creating Development KPIs and reporting as appropriate

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera aims to advance its platform and fulfill its mission of curing diseases by rewriting genetic code.

Company Stage

Series C

Total Funding

$518.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

-9%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera secured $300 million in Series C funding in April 2022.
  • Partnership with Gates Foundation supports development of in vivo treatments for sickle cell disease.
  • Boston's biotech hub provides Tessera access to talent, resources, and investment opportunities.

What critics are saying

  • Competition from CRISPR Therapeutics and Editas Medicine may impact Tessera's market share.
  • High development costs and complexity could strain finances if trials underperform.
  • Regulatory challenges may delay product launches, affecting Tessera's market entry.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics is pioneering Gene Writing, a novel approach in genetic medicine.
  • Their technology allows precise genome alterations, offering potential cures for genetic diseases.
  • Tessera's Gene Writing can target a wide range of genetic disorders effectively.

Help us improve and share your feedback! Did you find this helpful?